Clinical Trials for Pancreas Cancer

A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic Ductal Adenocarcinoma (PDAC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory/relapsed pancreatic ductal adenocarcinoma (ECOG 0–1) receive a single infusion of autologous B7-H3 (CD276)–targeted CAR-T cells incorporating an inducible caspase-9 safety switch. Dose-escalation evaluates safety/tolerability and feasibility; bridging therapy may be used pre-infusion.

ClinicalTrials.gov ID: NCT06158139

A Phase I/Ib Pilot Trial, Single Arm, Open Label, of Protein-Bound Paclitaxel, Cisplatin, and Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) in Patient With Metastatic Pancreatic Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with untreated metastatic pancreatic adenocarcinoma (including adenosquamous) with liver metastasis, ECOG 0–1, and no brain mets receive modified gemcitabine/cisplatin/nab-paclitaxel every 2 weeks plus continuous Tumor Treating Fields (TTF), followed by maintenance gemcitabine with TTF. TTF is a noninvasive device therapy delivering alternating electric fields that disrupt mitosis; key exclusions include significant cardiac conduction issues/implantable stimulators and inability to use the device.

ClinicalTrials.gov ID: NCT04605913

Phase I Pilot Study of Endoscopic Ultrasound Guided RFA in Advanced Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with locally advanced, unresectable, non-metastatic PDAC (ECOG 0–2) progressing after first-line therapy receive ongoing second- or third-line chemotherapy plus endoscopic ultrasound–guided radiofrequency ablation (EUS-RFA) of 1–4 cm, endoscopically accessible tumors. EUS-RFA is a local thermal ablation delivered via EUS needle to induce coagulative necrosis, performed over three sessions alongside systemic therapy to assess safety/tolerability.

ClinicalTrials.gov ID: NCT05723107

A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated locally advanced/metastatic pancreatic adenocarcinoma (post–gemcitabine/nab-paclitaxel or FOLFIRINOX; ECOG 0–2) receive oral azeliragon, a small‑molecule RAGE antagonist targeting inflammatory signaling (HMGB1/S100/AGEs), using a loading then maintenance dosing schedule in a dose‑escalation, single‑arm study. Key exclusions include ECOG >2, short life expectancy, strong CYP2C8 inhibitors, malabsorption, and significant comorbidities.

ClinicalTrials.gov ID: NCT05766748

Phase I Trial of MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Untreated metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receiving mFOLFIRINOX plus oral zunsemetinib, an investigational inhibitor of the p38α–MK2 signaling axis intended to reduce proinflammatory cytokine expression and potentially chemosensitize tumors. Key exclusions include CNS metastases, ≥grade 2 neuropathy, significant ILD, QTcF >460 ms, strong CYP3A4/2C8 modulators, and QT‑prolonging drugs.

ClinicalTrials.gov ID: NCT06648434

Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with stage III locally advanced pancreatic adenocarcinoma receive irreversible electroporation of the primary tumor with peri-ablation systemic chemotherapy continued from their pre-IRE regimen (FOLFIRINOX or gemcitabine). The study assesses safety and progression outcomes of adding IRE to standard chemotherapy in this non-randomized single-arm setting.

ClinicalTrials.gov ID: NCT03484299

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN18.2-positive advanced/metastatic PDAC, gastric/GEJ, or biliary tract cancers (ECOG 0–1) after at least one prior systemic therapy receive AZD4360 monotherapy. AZD4360 is an investigational CLDN18.2-targeted agent (modality not disclosed) in first-in-human dose escalation/expansion to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT06921928

Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with locally advanced, unresectable, nonmetastatic pancreatic adenocarcinoma (ECOG 0–1), including those after induction chemotherapy, receive concurrent weekly gemcitabine plus nab-paclitaxel (microtubule inhibitor; radiosensitizer) with hypofractionated ablative proton therapy (67.5 Gy/15 fx), followed by surgical exploration if feasible. Excludes prior overlapping abdominal RT or significant neuropathy; evaluates dose tolerance, safety, response, and resection potential.

ClinicalTrials.gov ID: NCT03652428

A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors lacking effective standard options (broad basket with prioritized cohorts such as CRC, SCLC, HNSCC, NSCLC, pancreatic, and bladder; some genomically enriched) receive oral single‑agent CP-383 in dose escalation and tumor‑specific expansions. CP-383 is a first‑in‑class small molecule designed to modulate lipid‑binding pockets on oncogenic proteins (exact target undisclosed).

ClinicalTrials.gov ID: NCT07030257

A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic urothelial/bladder cancer, NSCLC, HNSCC, esophageal cancer, or pancreatic adenocarcinoma (ECOG 0–1) receive PF-08046876, an ITGB6-targeted antibody–drug conjugate delivering a topoisomerase I payload, as IV monotherapy after prior standard therapy (≤2 prior lines in Part 2). Dose escalation/optimization and tumor-specific expansions assess safety, PK, and preliminary activity; excludes prior camptothecin/topo I ADC exposure and significant GI or pulmonary comorbidities.

ClinicalTrials.gov ID: NCT07090499